在炎症性肠病中使用抗氧化剂疗法:对随机临床试验进行系统审查和元分析
José Israel Rodrigues Junior1, Joice Kelly Gomes de Vasconcelos1, Lylian Ellen Militão Dos Santos Xavier2
1Faculdade de Nutrição (FANUT), Universidade Federal de Alagoas (UFAL), Maceió 57072-970, Brazil.
Pharmaceuticals (Basel, Switzerland)
|October 28, 2023
概括
这一系统性审查发现,虽然抗氧化剂补充可能有助于管理炎症性肠道疾病 (IBD),但需要更多的研究. 超氧化物脱酶 (SOD) 水平显著调节,但其他氧化应激标志物没有持续受到影响.
科学领域:
- 胃肠病学 胃肠病学
- 生物化学 生物化学
- 临床医学 临床医学
背景情况:
- 炎症性肠病 (IBD) 是一种慢性疾病,其特征是炎症.
- 氧化应激在IBD的发病过程中起着重要作用.
- 目前的治疗方法旨在减少炎症,但可能无法完全解决氧化应激.
研究的目的:
- 系统地审查和元分析IBD治疗对氧化应激生物标志物和细胞因子水平的影响.
- 评估抗氧化剂补充剂在治疗IBD中的潜力.
- 确定有关IBD治疗中的氧化应激研究中的差距.
主要方法:
- 来自PubMed,Science Direct和Scopus的临床试验的系统审查.
- 对8项精选的研究进行的元分析,重点关注抗氧化能力,超氧化物脱酶 (SOD) 和甲 (MDA).
- 纳入标准被应用到选相关研究进行分析.
主要成果:
- 治疗显著调节了氧化物失调酶 (SOD) 的水平 (RR = 0.3764,p = 0.035).
- 抗氧化能力和甲酸 (MDA) 水平没有显著的调节.
- 对替代疗法及其对IBD氧化应激的影响的研究是有限的.
结论:
- 抗氧化剂补充剂通过调节SOD显示IBD管理的潜力.
- 进一步的研究对于了解抗氧化剂对氧化应激生物标志物和IBD中的细胞因子的影响至关重要.
- 对IBD患者的改善治疗策略可能来自对氧化应激调节的更深入理解.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
134
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
134
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
338
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
338
Drugs for Treatment of Ulcerative Colitis in IBD
149
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
149
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
170
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
170
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
122
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
122
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
148
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
148


